已收盘 05-08 16:00:00 美东时间
-0.770
-13.60%
BTIG analyst Jeet Mukherjee maintains Verastem (NASDAQ:VSTM) with a Buy and lowers the price target from $19 to $18.
05-08 20:10
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the launch of its Reimagine Recurrent Low-Grade Serous
04-30 19:38
今日重点评级关注:Ascendiant Capital:维持Allarity Therapeutics"买入"评级,目标价从9.5美元升至9.75美元;Citizens:维持戴夫"跑赢大市"评级,目标价从310美元升至335美元
04-13 14:07
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $18 price target.
04-11 01:26
今日重点评级关注:Freedom Capital Markets:维持LifeMD"买入"评级,目标价从8美元升至10美元;Chardan Capital:维持Opus Genetics"买入"评级,目标价从9美元升至11美元
03-13 09:59
BTIG analyst Jeet Mukherjee assumes Verastem (NASDAQ:VSTM) with a Buy rating and announces Price Target of $19.
03-12 18:59
The Q4 earnings report for Verastem (NASDAQ:VSTM) was released on Wednesday, Ma...
03-05 05:07
Verastem (NASDAQ:VSTM) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.53) by 9.26 percent. This is a 20 percent increase over losses of $(0.60) per share from the same
03-05 05:02
Companies Reporting Before The Bell • Dingdong (Cayman) (NYSE:DDL) is estimated...
03-04 19:11
Verastem (NASDAQ:VSTM) is gearing up to announce its quarterly earnings on Wedn...
03-04 01:03